PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
This study is a prospective, open-label, phase II clinical study for patients with HR+/HER2- advanced breast cancer.
Trial Details
- NCT ID
- NCT05759546
- Phase
- PHASE2
- Sponsor
- Fudan University
- Status
- RECRUITING
- Cancer Type
- Breast Cancer
- Interventions
- Fluzoparib
- Dalpiciclib
- Fulvestrant/AI
- Locations (sample)
- Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
- Females ≥18 years and ≤ 75 years old;
- Histologically confirmed HR + / HER2- invasive breast cancer (specific definition: immunohistochemical detection of ER\> 10% tumor cell positive is…
- Subtype of similarity network fusion-3 (SNF-3) confirmed by the Department of Pathology and Key Laboratory of Breast Cancer of Fudan University Aff…
- Measurable disease according to Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1); or unmeasurable lytic or mixed (osteolytic + osteo…
For full eligibility, visit ClinicalTrials.gov.
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →